In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines.

Abstract

Antisense and Nucleic Acid Drug DevelopmentVol. 7, No. 3 In Vivo Pharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous GuanosinesSUDHIR AGRAWAL, WEITIAN TAN, QUIYIN CAI, XIAOWEI XIE, and RUIWEN ZHANGSUDHIR AGRAWALSearch for more papers by this author, WEITIAN TANSearch for more papers by this author, QUIYIN CAISearch for more papers by this author, XIAOWEI XIESearch for more papers by this author, and RUIWEN ZHANGSearch for more papers by this authorPublished Online:30 Jan 2009https://doi.org/10.1089/oli.1.1997.7.245AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byAllometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-22119 December 2019 | Cancers, Vol. 12, No. 1Oligonucleotide-based Toll-like Receptor Antagonists and Therapeutic ApplicationsSynthetic Agonists of Toll-like Receptors and Therapeutic ApplicationsTissue Distribution, Metabolism, and Clearance22 June 2018Hybridization-Independent Effects22 June 2018A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice12 June 2013 | Autoimmunity, Vol. 46, No. 7Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 98 February 2013 | Nucleic Acids Research, Vol. 41, No. 6Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides3 August 2011Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 922 December 2008 | Journal of Medicinal Chemistry, Vol. 52, No. 2Pharmacokinetics of Oligonucleotides28 September 2007Antisense Strategies for Oncogene InactivationSeminars in Oncology, Vol. 32, No. 6DNA-based therapeutics and DNA delivery systems: A comprehensive reviewThe AAPS Journal, Vol. 7, No. 1Rapid Screening Method for Antisense Oligonucleotides Against Human Growth Factor Receptor p185erbB-2 Anke Rohmann, Dirk Lochmann, Jörg Weyermann, Wolf M. Bertling, Theodor Dingermann, and Andreas Zimmer8 July 2004 | Oligonucleotides, Vol. 14, No. 1Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNAAnnals of the New York Academy of Sciences, Vol. 1002, No. 1Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 OligonucleotidesAnnals of the New York Academy of Sciences, Vol. 1002, No. 1Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cellsBiochemical and Biophysical Research Communications, Vol. 310, No. 4Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology11 November 2002 | Proceedings of the National Academy of Sciences, Vol. 99, No. 24Antinociceptive effects after intrathecal administration of phosphodiester-, 2′-O-allyl-, and C-5-propyne-modified antisense oligodeoxynucleotides targeting the NMDAR1 subunit in mouseMolecular Brain Research, Vol. 86, No. 1-2Biodistribution and Metabolism of a Mixed Backbone Oligonucleotide (GEM 231) Following Single and Multiple Dose Administration in Mice MARY RUSCKOWSKI, TONG QU, ALLYSEN ROSKEY, and SUDHIR AGRAWAL30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 10, No. 5Antisense therapeutics: is it as simple as complementary base recognition?Molecular Medicine Today, Vol. 6, No. 2Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological propertiesBioorganic & Medicinal Chemistry, Vol. 8, No. 1Importance of nucleotide sequence and chemical modifications of antisense oligonucleotidesBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, Vol. 1489, No. 1Abstracts from the Third Annual NIH Symposium on Therapeutic Oligonucleotides Yoon S. Cho-Chung, Serge Beaucage, Victor Marquez, Leonard Neckers, and Paul F. Torrence30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 9, No. 4Nucleic Acid BiotechnologyAnnual Review of Biomedical Engineering, Vol. 1, No. 1Pharmacokinetics and Metabolism of an Oligodeoxynucleotide Phosphorothioate (GEM91®) in Cynomolgus Monkeys Following Intravenous Infusion J. MICHAEL GRINDEL, TIMOTHY J. MUSICK, ZHIWEI JIANG, ALLYSEN ROSKEY, and SUDHIR AGRAWAL30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 8, No. 1Antisense therapeuticsCurrent Opinion in Chemical Biology, Vol. 2, No. 4Pharmacokinetics, Tissue Distribution, and Safety of P-Ethoxy Oligonucleotides Incorporated in Liposomes28 September 2008 | Journal of Liposome Research, Vol. 8, No. 2Agonists of Toll-Like Receptor 9 Volume 7Issue 3Jun 1997 To cite this article:SUDHIR AGRAWAL, WEITIAN TAN, QUIYIN CAI, XIAOWEI XIE, and RUIWEN ZHANG.In Vivo Pharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous Guanosines.Antisense and Nucleic Acid Drug Development.Jun 1997.245-249.http://doi.org/10.1089/oli.1.1997.7.245Published in Volume: 7 Issue 3: January 30, 2009PDF download